Krystal Biotech Inc (KRYS)

Current ratio

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Total current assets	US$ in thousands	602,248	587,909	582,128	484,004	355,429	383,779	397,578	428,770	437,998	442,267	345,812	369,927	405,826	275,058	287,652	298,539	188,329	195,880	204,435	196,203
Total current liabilities	US$ in thousands	47,589	33,094	27,583	23,898	35,076	28,847	28,032	34,427	60,437	25,736	35,779	18,119	9,144	15,452	7,198	5,831	4,061	3,327	3,726	3,940
Current ratio		12.66	17.76	21.10	20.25	10.13	13.30	14.18	12.45	7.25	17.18	9.67	20.42	44.38	17.80	39.96	51.20	46.38	58.88	54.87	49.80

March 31, 2024 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $602,248K ÷ $47,589K
= 12.66

The current ratio of Krystal Biotech Inc has exhibited fluctuations over the past few quarters, ranging from a low of 7.25 to a high of 58.88. Currently, as of March 31, 2024, the company's current ratio stands at 12.66. This indicates that Krystal Biotech Inc has $12.66 in current assets for every $1 in current liabilities, reflecting a strong liquidity position.

The upward trend in the current ratio from the last quarter of 2023 to the first quarter of 2024 suggests an improvement in the company's ability to meet its short-term obligations. However, it is noteworthy that the current ratio has shown significant volatility over the analyzed periods, indicating potential fluctuations in the company's liquidity position.

It is important for Krystal Biotech Inc to carefully monitor its current ratio and ensure it remains at a level that allows for efficient management of its short-term financial obligations while also considering the cyclical nature of the biotech industry. Additional analysis of other financial ratios and qualitative factors would provide a more comprehensive assessment of the company's overall financial health.